This Is How Rasonque Works, the New Pancreatic Cancer Pill that Almost Doubles Survival
5 Articles
5 Articles
The medicine Daraxonrasib blocks a protein that favors the growth of cancer cells. In a study of 500 patients, median survival increased from 6.7 to 12.4 months compared to chemotherapy.
Metastatic pancreas cancer, positive opinion of the Ema for Daraxonrasib: median survival from 6.7 to 12.4 months. Aifa reimburses Onivyde in the front line. The post Metastatic pancreas cancer, the Ema opens to a tablet that almost doubles survival appeared first on BlogSicily - Latest news from Sicily.
The European Medicines Committee CHMP has issued a positive opinion for Rasonque (daraxonrasib), according to the Evaluation Board of… Pancreatic cancer drug receives positive EU opinion
Treatment with daraxonrasib showed a median overall survival of 12.4 months compared with 6.7 months with chemotherapy in patients with metastatic adenocarcinoma of the pancreas. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that daraxonrasib, an oral treatment for adults with metastatic adenocarcinoma of the pancreas, meaning cancer that has spread to other parts of the body, wh…
The European Medicines Agency (EMA) has recommended the approval of a new drug for the treatment of advanced pancreatic cancer. The drug, called “daraxonrasib”, is recommended for adults with pancreatic cancer, which is......
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
